U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C20H24ClN3S
Molecular Weight 373.943
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PROCHLORPERAZINE

SMILES

CN1CCN(CCCN2C3=C(SC4=C2C=C(Cl)C=C4)C=CC=C3)CC1

InChI

InChIKey=WIKYUJGCLQQFNW-UHFFFAOYSA-N
InChI=1S/C20H24ClN3S/c1-22-11-13-23(14-12-22)9-4-10-24-17-5-2-3-6-19(17)25-20-8-7-16(21)15-18(20)24/h2-3,5-8,15H,4,9-14H2,1H3

HIDE SMILES / InChI

Molecular Formula C20H24ClN3S
Molecular Weight 373.943
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including http://apm.amegroups.com/article/view/1039/1266

Prochlorperazine is a piperazine phenothiazine antipsychotic which block postsynaptic mesolimbic dopaminergic receptors in the brain and has antiemetic effects by its antagonist actions in the D2 dopamine receptors in the chemoreceptor trigger zone. It also exhibits alpha-adrenergic blocking effect on α1 receptros and may depress the release of hypothalamic and hypophyseal hormones. Prochlorperazine is used for the control of severe nausea and vomiting, for the treatment of schizophrenia. Prochlorperazine is effective for the short-term treatment of generalized non-psychotic anxiety. Prochlorperazine may be an effective treatment of acute headaches and refractory chronic daily headache.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
COMPAZINE

Approved Use

To control severe nausea and vomiting. For the treatment of schizophrenia. Prochlorperazine is effective for the short-term treatment of generalized non-psychotic anxiety.

Launch Date

1959
Primary
COMPAZINE

Approved Use

To control severe nausea and vomiting. For the treatment of schizophrenia. Prochlorperazine is effective for the short-term treatment of generalized non-psychotic anxiety.

Launch Date

1959
Primary
COMPAZINE

Approved Use

To control severe nausea and vomiting. For the treatment of schizophrenia. Prochlorperazine is effective for the short-term treatment of generalized non-psychotic anxiety.

Launch Date

1959
Primary
COMPAZINE

Approved Use

To control severe nausea and vomiting. For the treatment of schizophrenia. Prochlorperazine is effective for the short-term treatment of generalized non-psychotic anxiety.

Launch Date

1959
Primary
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
3.9 ng/mL
25 mg 2 times / day multiple, oral
dose: 25 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
PROCHLORPERAZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
4 ng/mL
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PROCHLORPERAZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
32.3 ng × h/mL
25 mg 2 times / day multiple, oral
dose: 25 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
PROCHLORPERAZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
18.1 h
25 mg 2 times / day multiple, oral
dose: 25 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
PROCHLORPERAZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
8 h
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PROCHLORPERAZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
9 h
12.5 mg/kg single, intravenous
dose: 12.5 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
PROCHLORPERAZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
180 mg/m2 1 times / day multiple, intravenous
MTD
Dose: 180 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 180 mg/m2, 1 times / day
Co-administed with::
doxorubicin, i.v.(60 mg/m2; q.d.)
Sources: Page: p.380
unhealthy, 38-77
n = 4
Health Status: unhealthy
Condition: Cancer
Age Group: 38-77
Sex: M+F
Population Size: 4
Sources: Page: p.380
DLT: Sedation, Hypotension...
Disc. AE: Akathisia...
Dose limiting toxicities:
Sedation (grade 3, 25%)
Hypotension (grade 3, 25%)
AEs leading to
discontinuation/dose reduction:
Akathisia (50%)
Sources: Page: p.380
1.2 mg/kg 1 times / day multiple, intravenous
MTD
Dose: 1.2 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 1.2 mg/kg, 1 times / day
Sources: Page: p.1469
unhealthy
n = 3
Health Status: unhealthy
Condition: Nausea|Vomiting
Sex: M+F
Population Size: 3
Sources: Page: p.1469
DLT: Hypotension, Restlessness...
Dose limiting toxicities:
Hypotension (33.3%)
Restlessness (100%)
Sources: Page: p.1469
AEs

AEs

AESignificanceDosePopulation
Akathisia 50%
Disc. AE
180 mg/m2 1 times / day multiple, intravenous
MTD
Dose: 180 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 180 mg/m2, 1 times / day
Co-administed with::
doxorubicin, i.v.(60 mg/m2; q.d.)
Sources: Page: p.380
unhealthy, 38-77
n = 4
Health Status: unhealthy
Condition: Cancer
Age Group: 38-77
Sex: M+F
Population Size: 4
Sources: Page: p.380
Hypotension grade 3, 25%
DLT
180 mg/m2 1 times / day multiple, intravenous
MTD
Dose: 180 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 180 mg/m2, 1 times / day
Co-administed with::
doxorubicin, i.v.(60 mg/m2; q.d.)
Sources: Page: p.380
unhealthy, 38-77
n = 4
Health Status: unhealthy
Condition: Cancer
Age Group: 38-77
Sex: M+F
Population Size: 4
Sources: Page: p.380
Sedation grade 3, 25%
DLT
180 mg/m2 1 times / day multiple, intravenous
MTD
Dose: 180 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 180 mg/m2, 1 times / day
Co-administed with::
doxorubicin, i.v.(60 mg/m2; q.d.)
Sources: Page: p.380
unhealthy, 38-77
n = 4
Health Status: unhealthy
Condition: Cancer
Age Group: 38-77
Sex: M+F
Population Size: 4
Sources: Page: p.380
Restlessness 100%
DLT
1.2 mg/kg 1 times / day multiple, intravenous
MTD
Dose: 1.2 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 1.2 mg/kg, 1 times / day
Sources: Page: p.1469
unhealthy
n = 3
Health Status: unhealthy
Condition: Nausea|Vomiting
Sex: M+F
Population Size: 3
Sources: Page: p.1469
Hypotension 33.3%
DLT
1.2 mg/kg 1 times / day multiple, intravenous
MTD
Dose: 1.2 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 1.2 mg/kg, 1 times / day
Sources: Page: p.1469
unhealthy
n = 3
Health Status: unhealthy
Condition: Nausea|Vomiting
Sex: M+F
Population Size: 3
Sources: Page: p.1469
PubMed

PubMed

TitleDatePubMed
[Diagnostic image (17). Acute dystonia induced by prochlorperazine].
2000 Dec 23
Anti-emetics.
2001
Sedation and analgesia for transvaginal oocyte retrieval: an audit resulting in a change of clinical practice.
2001
Ondansetron: a review of its use as an antiemetic in children.
2001
Continuous infusion prochlorperazine: pharmacokinetics, antiemetic efficacy, and feasibility of high-dose therapy.
2001 Apr
Tolerability and effectiveness of prochlorperazine for intractable migraine in children.
2001 Apr
[Inactivation of Trypanosoma cruzi trypanothione reductase by phenothiazine cationic free radicals].
2001 Jan-Mar
Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review.
2001 Jul 7
Headache in the emergency department.
2001 Jun
Pegylated liposomal doxorubicin: tolerability and toxicity.
2001 Jun
[A case report. Drugs can be administered via colostomy but the scientific support is negligible].
2001 May 9
Amphotericin B-induced seizures in a patient with AIDS.
2001 Sep
Incompatibility of prochlorperizine and ketoprofen.
2001 Sep
Droperidol vs. prochlorperazine for benign headaches in the emergency department.
2001 Sep
Oral mucosal drug delivery: clinical pharmacokinetics and therapeutic applications.
2002
Myeloperoxidase-generated phenothiazine cation radicals inactivate Trypanosoma cruzi dihydrolipoamide dehydrogenase.
2002 Apr-Jun
Identification and characterization of 17 phenothiazine compounds by capillary high-performance liquid chromatography/fast atom bombardment mass spectrometry.
2002 Dec
Upper airway obstruction resulting from an antiemetic.
2002 Dec
Antimicrobial potentiality of a phenothiazine group of antipsychotic drug-prochlorperazine.
2002 Jul
Medical management of Meniere's disease.
2002 Jun
Akathisia: problematic but preventable.
2002 May
Antiemetic use in pediatric gastroenteritis: a national survey of emergency physicians, pediatricians, and pediatric emergency physicians.
2002 Nov-Dec
Efficacy and tolerability of prochlorperazine buccal tablets in treatment of acute migraine.
2002 Oct
Indomethacin, caffeine and prochlorperazine alone and combined revert hyperalgesia in in vivo models of migraine.
2002 Sep
The efficacy and cost-effectiveness of prophylactic 5-hydroxytryptamine3 receptor antagonists: tropisetron, ondansetron and dolasetron.
2003 Feb
Akathisia can be reduced by lowering the dose of D2 receptor antagonists.
2003 Feb
Serotonin syndrome induced by low-dose venlafaxine.
2003 Feb
Variations among emergency departments in the treatment of benign headache.
2003 Jan
In vitro human plasma leucine(5)-enkephalin degradation is inhibited by a select number of drugs with the phenothiazine molecule in their chemical structure.
2003 Jan
Surgeon-led initiatives cut costs and enhance the quality of endoscopic and laparoscopic procedures.
2003 Jul-Sep
Intravenous sodium valproate versus prochlorperazine for the emergency department treatment of acute migraine headaches: a prospective, randomized, double-blind trial.
2003 Jun
Phenothiazine radicals inactivate Trypanosoma cruzi dihydrolipoamide dehydrogenase: enzyme protection by radical scavengers.
2003 Mar
Extrapyramidal reactions to ondansetron: cross-reactivity between ondansetron and prochlorperazine?
2003 May
Comparison of three outpatient regimens in the management of nausea and vomiting in pregnancy.
2003 Oct
Aborting a prolonged migrainous aura with intravenous prochlorperazine and magnesium sulfate.
2003 Sep
Efficacy of a fixed combination of indomethacin, prochlorperazine, and caffeine versus sumatriptan in acute treatment of multiple migraine attacks: a multicenter, randomized, crossover trial.
2003 Sep
Prochlorperazine-induced cholestasis in a patient with alpha-1 antitrypsin deficiency.
2003 Sep-Oct
Prochlorperazine more effective than ketorolac for pediatric migraine.
2004 Jun
Antibacterial property of the antipsychotic agent prochlorperazine, and its synergism with methdilazine.
2005
Clinical practice guidelines on antiemetics in oncology.
2005 Dec
Bioavailability and metabolism of prochlorperazine administered via the buccal and oral delivery route.
2005 Dec
Acute hypersensitivity reaction to ferric gluconate in a premedicated patient.
2005 Dec
In vitro activity of phenothiazine derivatives in Enterococcus faecalis and Enterococcus faecium.
2005 Jan
The antipsychotic and antiemetic drug prochlorperazine delays the ventricular repolarization of the in situ canine heart.
2005 Jan
A phase I clinical trial of continual alternating etoposide and topotecan in refractory solid tumours.
2005 Jul 11
Acupuncture therapy rapidly terminates intractable hiccups complicating acute myocardial infarction.
2005 Mar
Analysis of phenothiazines in human body fluids using disk solid-phase extraction and liquid chromatography.
2005 Nov-Dec
[Three cases of drug-induced akathisia due to antiemetics during cancer palliative care].
2006 Feb
Chronic severe dystonia after single exposure to antiemetics.
2006 Jan
Antiemetics in the ED: a randomized controlled trial comparing 3 common agents.
2006 Mar
Patents

Sample Use Guides

DOSAGE AND ADMINISTRATION–ADULTS 1. To Control Severe Nausea and Vomiting: Adjust dosage to the response of the individual. Begin with the lowest recommended dosage. Oral Dosage–Tablets: Usually one 5 mg or 10 mg tablet 3 or 4 times daily. Daily dosages above 40 mg should be used only in resistant cases. Spansule capsules: Initially, usually one 15 mg capsule on arising or one 10 mg capsule q12h. Daily doses above 40 mg should be used only in resistant cases. 11 Rectal Dosage: 25 mg twice daily. I.M. Dosage: Initially 5 to 10 mg (1 to 2 mL) injected deeply into the upper outer quadrant of the buttock. If necessary, repeat every 3 or 4 hours. Total I.M. dosage should not exceed 40 mg per day. I.V. Dosage: 2½ to 10 mg (½ to 2 mL) by slow I.V. injection or infusion at a rate not to exceed 5 mg per minute. Compazine Injection may be administered either undiluted or diluted in isotonic solution. A single dose of the drug should not exceed 10 mg; total I.V. dosage should not exceed 40 mg per day. When administered I.V., do not use bolus injection. Hypotension is a possibility if the drug is given by I.V. injection or infusion. 2. Adult Surgery (for severe nausea and vomiting): Total parenteral dosage should not exceed 40 mg per day. Hypotension is a possibility if the drug is given by I.V. injection or infusion. I.M. Dosage: 5 to 10 mg (1 to 2 mL) 1 to 2 hours before induction of anesthesia (repeat once in 30 minutes, if necessary), or to control acute symptoms during and after surgery (repeat once if necessary). I.V. Dosage: 5 to 10 mg (1 to 2 mL) as a slow I.V. injection or infusion 15 to 30 minutes before induction of anesthesia, or to control acute symptoms during or after surgery. Repeat once if necessary. Compazine (prochlorperazine) may be administered either undiluted or diluted in isotonic solution, but a single dose of the drug should not exceed 10 mg. The rate of administration should not exceed 5 mg per minute. When administered I.V., do not use bolus injection. 3. In Adult Psychiatric Disorders: Adjust dosage to the response of the individual and according to the severity of the condition. Begin with the lowest recommended dose. Although response ordinarily is seen within a day or 2, longer treatment is usually required before maximal improvement is seen. Oral Dosage: Non-Psychotic Anxiety–Usual dosage is 5 mg 3 or 4 times daily; by Spansule capsule, usually one 15 mg capsule on arising or one 10 mg capsule q12h. Do not administer in doses of more than 20 mg per day or for longer than 12 weeks. Psychotic Disorders including Schizophrenia–In relatively mild conditions, as seen in private psychiatric practice or in outpatient clinics, dosage is 5 or 10 mg 3 or 4 times daily. In moderate to severe conditions, for hospitalized or adequately supervised patients, usual starting dosage is 10 mg 3 or 4 times daily. Increase dosage gradually until symptoms are controlled or side effects become bothersome. When dosage is increased by small increments every 2 or 3 days, side effects either do not occur or are easily controlled. Some patients respond satisfactorily on 50 to 75 mg daily. In more severe disturbances, optimum dosage is usually 100 to 150 mg daily. I.M. Dosage: For immediate control of adult schizophrenic patients with severe symptomatology, inject an initial dose of 10 to 20 mg (2 to 4 mL) deeply into the upper outer quadrant of the buttock. Many patients respond shortly after the first injection. If necessary, however, repeat the initial dose every 2 to 4 hours (or, in resistant cases, every hour) to gain control of the patient. More than three or four doses are seldom necessary. After control is achieved, switch patient to an oral form of the drug at the same dosage level or higher. If, in rare cases, parenteral therapy is needed for a prolonged period, give 10 to 20 mg (2 to 4 mL) every 4 to 6 hours. Pain and irritation at the site of injection have seldom occurred. Subcutaneous administration is not advisable because of local irritation.
Route of Administration: Other
In Vitro Use Guide
We have studied the effects of prochlorperazine on the activities of UDP-glucuronosyltransferase and glucose-6-phosphatase (glucose-6-P'ase) in rat liver microsomes. The activity of UDP-glucuronosyltransferase was increased in a graded fashion by addition of prochlorperazine. Maximal stimulation occurred at 1 mg prochlorperazine to 2 mg microsomal protein, which resulted in a 6-fold increase in activity.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:21:26 GMT 2023
Edited
by admin
on Fri Dec 15 15:21:26 GMT 2023
Record UNII
YHP6YLT61T
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PROCHLORPERAZINE
HSDB   INN   JAN   MART.   MI   ORANGE BOOK   USP   VANDF   WHO-DD  
INN  
Official Name English
PROCHLORPERAZINE [HSDB]
Common Name English
10H-PHENOTHIAZINE, 2-CHLORO-10-(3-(4-METHYL-1-PIPERAZINYL)PROPYL
Common Name English
COMPRO
Brand Name English
PROCHLORPERAZINE [MART.]
Common Name English
Prochlorperazine [WHO-DD]
Common Name English
prochlorperazine [INN]
Common Name English
PROCHLORPERAZINE [JAN]
Common Name English
COMPAZINE
Brand Name English
PROCHLORPERAZINE [MI]
Common Name English
2-Chloro-10-[3-(4-methyl-1-piperazinyl)propyl]phenothiazine
Systematic Name English
PROCHLORPERAZINE [ORANGE BOOK]
Common Name English
2-CHLORO-10-(3-(4-METHYLPIPERAZIN-1-YL)PROPYL)-10H-PHENOTHIAZINE
Systematic Name English
PROCHLORPERAZINE [USP MONOGRAPH]
Common Name English
PROCHLORPERAZINE [VANDF]
Common Name English
Classification Tree Code System Code
NDF-RT N0000007544
Created by admin on Fri Dec 15 15:21:26 GMT 2023 , Edited by admin on Fri Dec 15 15:21:26 GMT 2023
LIVERTOX NBK548122
Created by admin on Fri Dec 15 15:21:26 GMT 2023 , Edited by admin on Fri Dec 15 15:21:26 GMT 2023
WHO-ATC N05AB04
Created by admin on Fri Dec 15 15:21:26 GMT 2023 , Edited by admin on Fri Dec 15 15:21:26 GMT 2023
CFR 21 CFR 520.1920
Created by admin on Fri Dec 15 15:21:26 GMT 2023 , Edited by admin on Fri Dec 15 15:21:26 GMT 2023
CFR 21 CFR 520.1921
Created by admin on Fri Dec 15 15:21:26 GMT 2023 , Edited by admin on Fri Dec 15 15:21:26 GMT 2023
NDF-RT N0000007544
Created by admin on Fri Dec 15 15:21:26 GMT 2023 , Edited by admin on Fri Dec 15 15:21:26 GMT 2023
NDF-RT N0000007544
Created by admin on Fri Dec 15 15:21:26 GMT 2023 , Edited by admin on Fri Dec 15 15:21:26 GMT 2023
CFR 21 CFR 522.1920
Created by admin on Fri Dec 15 15:21:26 GMT 2023 , Edited by admin on Fri Dec 15 15:21:26 GMT 2023
NCI_THESAURUS C740
Created by admin on Fri Dec 15 15:21:26 GMT 2023 , Edited by admin on Fri Dec 15 15:21:26 GMT 2023
NDF-RT N0000175746
Created by admin on Fri Dec 15 15:21:26 GMT 2023 , Edited by admin on Fri Dec 15 15:21:26 GMT 2023
WHO-VATC QN05AB04
Created by admin on Fri Dec 15 15:21:26 GMT 2023 , Edited by admin on Fri Dec 15 15:21:26 GMT 2023
Code System Code Type Description
IUPHAR
7279
Created by admin on Fri Dec 15 15:21:26 GMT 2023 , Edited by admin on Fri Dec 15 15:21:26 GMT 2023
PRIMARY
DRUG BANK
DB00433
Created by admin on Fri Dec 15 15:21:26 GMT 2023 , Edited by admin on Fri Dec 15 15:21:26 GMT 2023
PRIMARY
CHEBI
8435
Created by admin on Fri Dec 15 15:21:26 GMT 2023 , Edited by admin on Fri Dec 15 15:21:26 GMT 2023
PRIMARY
HSDB
3171
Created by admin on Fri Dec 15 15:21:26 GMT 2023 , Edited by admin on Fri Dec 15 15:21:26 GMT 2023
PRIMARY
NCI_THESAURUS
C774
Created by admin on Fri Dec 15 15:21:26 GMT 2023 , Edited by admin on Fri Dec 15 15:21:26 GMT 2023
PRIMARY
EVMPD
SUB10059MIG
Created by admin on Fri Dec 15 15:21:26 GMT 2023 , Edited by admin on Fri Dec 15 15:21:26 GMT 2023
PRIMARY
LACTMED
Prochlorperazine
Created by admin on Fri Dec 15 15:21:26 GMT 2023 , Edited by admin on Fri Dec 15 15:21:26 GMT 2023
PRIMARY
MERCK INDEX
m9149
Created by admin on Fri Dec 15 15:21:26 GMT 2023 , Edited by admin on Fri Dec 15 15:21:26 GMT 2023
PRIMARY Merck Index
EPA CompTox
DTXSID7023514
Created by admin on Fri Dec 15 15:21:26 GMT 2023 , Edited by admin on Fri Dec 15 15:21:26 GMT 2023
PRIMARY
WIKIPEDIA
Prochlorperazine
Created by admin on Fri Dec 15 15:21:26 GMT 2023 , Edited by admin on Fri Dec 15 15:21:26 GMT 2023
PRIMARY
ECHA (EC/EINECS)
200-379-4
Created by admin on Fri Dec 15 15:21:26 GMT 2023 , Edited by admin on Fri Dec 15 15:21:26 GMT 2023
PRIMARY
CAS
58-38-8
Created by admin on Fri Dec 15 15:21:26 GMT 2023 , Edited by admin on Fri Dec 15 15:21:26 GMT 2023
PRIMARY
DAILYMED
YHP6YLT61T
Created by admin on Fri Dec 15 15:21:26 GMT 2023 , Edited by admin on Fri Dec 15 15:21:26 GMT 2023
PRIMARY
DRUG CENTRAL
2274
Created by admin on Fri Dec 15 15:21:26 GMT 2023 , Edited by admin on Fri Dec 15 15:21:26 GMT 2023
PRIMARY
PUBCHEM
4917
Created by admin on Fri Dec 15 15:21:26 GMT 2023 , Edited by admin on Fri Dec 15 15:21:26 GMT 2023
PRIMARY
ChEMBL
CHEMBL728
Created by admin on Fri Dec 15 15:21:26 GMT 2023 , Edited by admin on Fri Dec 15 15:21:26 GMT 2023
PRIMARY
MESH
D011346
Created by admin on Fri Dec 15 15:21:26 GMT 2023 , Edited by admin on Fri Dec 15 15:21:26 GMT 2023
PRIMARY
SMS_ID
100000092583
Created by admin on Fri Dec 15 15:21:26 GMT 2023 , Edited by admin on Fri Dec 15 15:21:26 GMT 2023
PRIMARY
FDA UNII
YHP6YLT61T
Created by admin on Fri Dec 15 15:21:26 GMT 2023 , Edited by admin on Fri Dec 15 15:21:26 GMT 2023
PRIMARY
INN
699
Created by admin on Fri Dec 15 15:21:26 GMT 2023 , Edited by admin on Fri Dec 15 15:21:26 GMT 2023
PRIMARY
RXCUI
8704
Created by admin on Fri Dec 15 15:21:26 GMT 2023 , Edited by admin on Fri Dec 15 15:21:26 GMT 2023
PRIMARY RxNorm
Related Record Type Details
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
BASIS OF STRENGTH->SUBSTANCE
ASSAY (TITRATION)
USP
Related Record Type Details
METABOLITE -> PARENT
METABOLITE -> PARENT
METABOLITE -> PARENT
METABOLITE -> PARENT
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC Elimination
PHARMACOKINETIC
Elimination
PHARMACOKINETIC
Elimination
PHARMACOKINETIC